Apr 24 2019

Fate Therapeutics Announces Five Presentations at the American Society of Gene & Cell Therapy 22nd Annual Meeting

SAN DIEGO, April 24, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Fate scientists and collaborators will present data highlighting the Company’s induced pluripotent stem cell (iPSC) product platform and its iPSC-derived cell product candidates at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting being held from April 28 - May 2, 2019 in Washington, D.C.

“Our strong scientific presence at ASGCT demonstrates the unique value of our proprietary iPSC product platform for gene editing and the development of universal, off-the-shelf, engineered cell therapies,” said Bob Valamehr, Ph.D., Chief Development Officer of Fate Therapeutics. “We look forward to showcasing the critical importance of characterizing and selecting a single clone from a heterogeneous population of engineered cells, our unmatched expertise in creating large numbers of clinical-grade NK cells and T cells from clonal master engineered iPSC lines, and the breadth of our highly-differentiated off-the-shelf cancer immunotherapy pipeline.”

Three oral and two poster presentations will highlight several product candidates from the Company’s universal, off-the-shelf, iPSC-derived cancer immunotherapy pipeline, including NK cell product candidates FT500 for the treatment of advanced solid tumors and FT516 for the treatment of advanced hematologic malignancies. FT500 is the first-ever iPSC-derived cell therapy to be administered to patients in the U.S., and FT516 is the first-ever engineered iPSC-derived cell therapy allowed for clinical investigation in the world. The Company’s iPSC-derived, dual-targeted CD16-CAR19 NK cell product candidate FT596 and its iPSC-derived, TCR-less, TRAC-targeted, 1XX CAR19 T-cell product candidate FT819, which is being developed under a collaboration with Memorial Sloan Kettering Cancer Center led by Michel Sadelain, M.D., Ph.D., will also be featured.

2019 ASGCT Oral Presentations

  • Workshop – CAR T and Related Immune Effector Cell Therapies
    Title:  iPSC-Derived Immune Effector Cells
    Presenter:  Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
    Date and Time:  Sunday, April 28, 2019, 3:30 PM - 6:00 PM
    Location:  Jefferson East
  • Session 132 – Induced Pluripotent Stem Cells
    Title:  Pluripotent Cell-Derived T and NK Cells as a Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy
    Presenter:  Bob Valamehr, Ph.D., Chief Development Officer, Fate Therapeutics
    Date and Time:  Monday, April 29, 2019, 1:30 PM - 3:00 PM
    Location:  Monroe Room
  • Session 134 – NK Cells versus NKT Cells
    Title:  Clinical Development of NK Cell Cancer Therapy
    Presenter:  Sarah Cooley, M.D., Senior V.P., Clinical Translation, Fate Therapeutics
    Date and Time:  Monday, April 29, 2019, 1:30 PM - 3:00 PM
    Location:  Georgetown Room

2019 ASGCT Poster Presentations

  • Poster 877 – iPSC Product Platform
    Title:  A Versatile Platform for Generation of Single-Cell Derived, Genetically Engineered, Fully Characterized Pluripotent Master Cell Lines as a Renewable Source for Off-the-Shelf Cell Therapy
    First Author:  Mochtar Pribadi, Ph.D., Scientist, Molecular Biology, Fate Therapeutics
    Date and Time:  Wednesday, May 1, 2019, 5:00 PM - 6:00 PM
    Location:  Columbia Hall
  • Poster 882 – CRISPR-based iPSC Generation
    Title: A Novel Platform Combining Chemical and CRISPRa Approaches for the Generation of Human iPSCs
    First Author:  Jason Dinella, Ph.D., Scientist, Reprogramming Biology, Fate Therapeutics
    Date and Time:  Wednesday, May 1, 2019, 5:00 PM - 6:00 PM
    Location:  Columbia Hall

About FT500
FT500 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line. FT500 is being investigated in an open-label, repeat-dose Phase 1 clinical trial for the treatment of advanced solid tumors in up to 64 patients, both as a monotherapy and in combination with FDA-approved checkpoint inhibitor therapy. Despite the favorable response rates observed with checkpoint inhibitor therapy, the majority of patients do not respond and many responders relapse. One common mechanism of resistance to checkpoint inhibitor therapy is associated with loss-of-function mutations in genes critical for antigen presentation. A potential strategy to overcome resistance is through the administration of allogeneic NK cells, which have the inherent capability to recognize and directly kill tumor cells with these mutations.

About FT516
FT516 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to express a novel high-affinity (158V), non-cleavable CD16 (hnCD16) Fc receptor. CD16 mediates antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. CD16 occurs in two variants, either with high (158V) or low (158F) affinity for the Fc domain of IgG1 antibodies. Numerous clinical studies with FDA-approved tumor-targeting antibodies, including rituximab, trastuzumab and cetuximab, have demonstrated that patients homozygous for the CD16 high-affinity variant (approximately 15% of patients) have improved clinical outcomes. In addition, the expression of CD16 can undergo considerable down-regulation in cancer patients, which significantly inhibits the immune system’s anti-tumor response. FT516 incorporates a novel CD16 Fc receptor, which has been modified to prevent its down-regulation and augment its binding to tumor-targeting antibodies for enhanced ADCC. The Company announced in February 2019 that the FDA allowed its FT516 IND application for the treatment of relapsed / refractory hematologic malignancies including in combination with certain FDA-approved monoclonal antibody therapies.

About Fate Therapeutics’ iPSC Product Platform
The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered in repeat doses to mediate more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf to treat many patients. As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is fraught with batch-to-batch and cell-to-cell variability that can affect safety and efficacy. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 100 issued patents and 100 pending patent applications.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as iPSC-derived NK cell and T-cell immunotherapies, with a focus on developing next-generation cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-associated antigens. The Company’s immuno-regulatory pipeline includes ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Company’s clinical studies and preclinical research and development programs. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results observed in prior studies of its product candidates, including preclinical studies and clinical trials of any of its product candidates, will not be observed in ongoing or future studies involving these product candidates, and the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, difficulties or delays in subject enrollment in current and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development). For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Christina Tartaglia
Stern Investor Relations, Inc.

Fate Therapeutics.jpg

Source: Fate Therapeutics, Inc.